NRx Pharmaceuticals quarterly loss shows clear improvement
NRx Pharmaceuticals quarterly loss narrows as the company begins its ketamine commercial launch, signaling a positive shift.
Prioritizing Your Well-being in Every Aspect of Life
NRx Pharmaceuticals quarterly loss narrows as the company begins its ketamine commercial launch, signaling a positive shift.
Cancer medicine price monitoring is crucial for ensuring affordability and access to essential treatments for patients.
FDA approval for Sunharbo marks a significant advancement in stroke risk reduction.
USFDA approval Olopatadine marks a significant milestone for Alembic Pharmaceuticals in the $20 million market.
Drug price monitoring has seen a 97% target achievement in Jharkhand, showcasing effective strategies in pharma regulation.
Ilumya FDA approval marks a significant advancement in psoriatic arthritis treatment options.